Immunovant, Inc. - Form 4 Filing

This SEC filing (Form 4) details a transaction by Jay Stout, Chief Technology Officer of Immunovant, Inc. On April 23, 2026, Stout sold 2,754 shares of Common Stock at a weighted average price of $29.62 per share. This sale was conducted to cover tax withholding obligations arising from the vesting of 6,250 restricted stock units (RSUs) granted on April 17, 2023. The sale was mandated by the issuer's "sell to cover" policy, as outlined in footnote F1. The transaction was executed in multiple tranches, with prices ranging from $29.23 to $30.00 per share, as noted in footnote F2. Following this transaction, Stout directly owns 251,685 shares of Immunovant, Inc. common stock. The filing was signed by Tiago Girao as attorney-in-fact for Jay Stout on April 24, 2026.